| abstract |
Provided is the use of spirothienopyran-piperidine derivative compounds, wherein the variables are as defined in the specification, in the treatment of alcohol use disorders. The compounds are antagonists of the ORL-1 receptor. Examples of the compounds include [2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4’-piperidine]-1’-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol and 2-chloro-1’-[[1-(2,6-difluorophenyl)-3-methylpyrazol-4-yl]methyl]-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4’-piperidine]. |